Wellington Management Group LLP Sells 8,780 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• Wellington Management reduced its IDEXX Laboratories stake by 1.2%, selling 8,780 shares and retaining 726,695 shares valued at approximately $382.6 million. Institutional investors collectively own 87.84% of the company.
• IDEXX reported quarterly EPS of $4.27, exceeding the $3.94 analyst estimate, while revenue rose 9.7% year over year to $1.22 billion. The company maintained fiscal 2026 EPS guidance of $14.69–$14.94.
• Analyst sentiment remains favorable but mixed, with six Buy ratings and four Holds; the stock carries a “Moderate Buy” consensus and an average price target of $747, versus a recent price of $554.99.

Wellington Management Group LLP trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 1.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 726,695 shares of the company's stock after selling 8,780 shares during the period. Wellington Management Group LLP owned about 0.92% of IDEXX Laboratories worth $382,561,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in IDXX. Elyxium Wealth LLC bought a new stake in IDEXX Laboratories during the 4th quarter valued at approximately $3,666,459,000. State Street Corp boosted its stake in IDEXX Laboratories by 4.0% in the 4th quarter. State Street Corp now owns 3,656,626 shares of the company's stock worth $2,473,817,000 after purchasing an additional 138,956 shares during the period. J. Stern & Co. LLP boosted its stake in IDEXX Laboratories by 23,694.7% in the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company's stock worth $1,795,072,000 after purchasing an additional 2,642,200 shares during the period. Geode Capital Management LLC grew its holdings in IDEXX Laboratories by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company's stock valued at $1,749,380,000 after buying an additional 86,263 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in IDEXX Laboratories by 13.8% during the 4th quarter. Invesco Ltd. now owns 1,502,218 shares of the company's stock valued at $1,016,296,000 after buying an additional 181,955 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Trading Up 1.8%

IDXX stock opened at $554.99 on Friday. The firm has a fifty day moving average price of $559.01 and a 200 day moving average price of $573.80. IDEXX Laboratories, Inc. has a fifty-two week low of $518.55 and a fifty-two week high of $769.98. The firm has a market cap of $43.72 billion, a PE ratio of 39.03, a price-to-earnings-growth ratio of 2.96 and a beta of 1.54. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter in the prior year, the firm earned $3.50 earnings per share. IDEXX Laboratories's revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

Analyst Ratings Changes

IDXX has been the topic of several research analyst reports. Citigroup boosted their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a "neutral" rating in a report on Wednesday, August 5th. Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Weiss Ratings downgraded shares of IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a report on Thursday. UBS Group boosted their price target on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 5th. Finally, Barclays cut their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a research report on Tuesday, August 11th. Six analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $747.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source